This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The latest results underscore that large pharma companies are making a “strategic retreat from some of their older drugs,” in China, ICBC International Researchanalyst Zhang Jialin said, as quoted by Bloomberg; instead, they’re focusing on growing market share for newer medicines. It’s not a completely unforeseen shift, though.
Kyle Gaan, a researchanalyst at GFI said in the same press release, “2020 was a breakout year for plant-based foods across the store. The growth can also be attributed to the placement of plant-based meat in the meat section, with refrigerated plant-based meat sales growing twice as fast as their frozen counterparts.
Designing risk sharing agreements Overall however, this warranty program is similar to previous performance-based risk sharing agreements, says Alex Watt, principal researchanalyst on GlobalData’s Price Intelligence team. GlobalData is the parent company of Pharmaceutical Technology.
Prior to that, Zhang was an equity researchanalyst at UBS in New York, where he covered the Major and Specialty Pharmaceutical Sector. Zhang will be responsible for all aspects of financial management and work closely with Novotech Holdings’ executive team to support the growth of the business across Asia.
Tirzepatide’s continuing stellar trial results as a weight loss injection have industry analysts putting up big predictions for the drug, particularly as a rival to Novo’s obesity drug Wegovy (tirzepatide is currently only approved for the treatment of type 2 diabetes under the trade name Mounjaro). billion in sales by 2026.
“With retail pharmacies entering the clinical trial space, investigative sites are left with little information around how this move will affect them or their patients,” says Emily Botto, Senior ResearchAnalyst at the Tufts Center for the Study of Drug Development (CSDD) and a scheduled presenter at the ACRP 2024 conference in Anaheim, Calif.
“With retail pharmacies entering the clinical trial space, investigative sites are left with little information around how this move will affect them or their patients,” says Emily Botto, Senior ResearchAnalyst at the Tufts Center for the Study of Drug Development (CSDD) and a scheduled presenter at the ACRP 2024 conference in Anaheim, Calif.
Prior to that, Dr. Zhang was an equity researchanalyst at UBS in New York , where he covered the Major and Specialty Pharmaceutical Sector. in its healthcare practice and conducted postdoctoral research in diabetes-related drug development at Boston University’s School of Medicine.
Author Bio: Gaurav Raj Bangarh Gaurav Raj Bangarh is a business researchanalyst and competitive intelligence professional. As a senior analyst at Roots Analysis, Gaurav has assisted several clients across multiple industry verticals within the healthcare domain.
To know more details on the molecular diagnostics market visit here [link] Author Bio: Gaurav Raj Bangarh Gaurav Raj Bangarh is a market researchanalyst and competitive intelligence professional. He is highly skilled at generating useful insights from unstructured / structured datasets.
For detailed insights about this domain, check out our report on Digital Twin Market Author’s Bio Gaurav Raj Bangarh is a business researchanalyst and competitive intelligence professional. As a senior analyst at Roots Analysis, Gaurav has assisted several clients across multiple industry verticals within the healthcare domain.
Author’s Bio Akarshika Singh is a business researchanalyst and competitive intelligence professional. As an experienced analyst at Roots Analysis, Akarshika has assisted several clients across multiple industry verticals within the healthcare domain.
Author Bio: Gaurav Raj Bangarh Gaurav Raj Bangarh is a business researchanalyst and competitive intelligence professional. As a senior analyst at Roots Analysis, Gaurav has assisted several clients across multiple industry verticals within the healthcare domain.
To know more details on the synthetic leather industry visit here [link] Author Bio: Rishav Thakur Rishav Thakur is a business researchanalyst and competitive intelligence professional. As an analyst at Roots Analysis, Rishav has assisted several clients across multiple industry verticals within the healthcare and chemical domain.
For detailed insights about this domain, check out our report on Antibody Discovery Services and Platforms Author’s Bio Gaurav Raj Bangarh is a business researchanalyst and competitive intelligence professional. He is highly skilled at generating useful insights from unstructured / structured datasets.
Author’s Bio Mahek Saini is a business researchanalyst and competitive intelligence professional. As an experienced analyst at Roots Analysis, Mahek has assisted several clients across multiple industry verticals within the healthcare domain.
Over the last twenty years, there has been a major rise in risk sharing agreements in the pharmaceutical space, said Alex Watt, GlobalData’s principal researchanalyst, at a recent webinar on the same topic.
I’ve been a member of ACRP since around 2007, and attending the conference has been on my bucket list for years, but work and life commitments have prevented me from going in the past, says Lori College, BS, CCRC, a Clinical ResearchAnalyst with the Duke Office of Clinical Research at Duke University School of Medicine, who was randomly selected (..)
To know more details on the market opportunity for subcutaneous biologics market, visit here >> [link] Author bio Dakshita has been working as a competent business researchanalyst since she joined Roots Analysis in 2023.
Authors Bio Akarshika Singh is a business researchanalyst and competitive intelligence professional. As an experienced analyst at Roots Analysis, Akarshika has assisted several clients across multiple industry verticals within the healthcare domain.
Nevertheless, this did not stop Trump from tweeting his disapproval of the document saying, “New FDA Rules make it more difficult for them to speed up vaccines for approval before Election Day. Just another political hit job! SteveFDA.”.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content